Infections associated with tumor necrosis factor-alpha antagonists.
about
Histoplasmosis: a clinical and laboratory updateA nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injuryInvasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitorsTNF superfamily: a growing saga of kidney injury modulators.Adult-onset immunodeficiency in Thailand and Taiwan.Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza.Anti-TNFα antibody infliximab treatment for an infant with fistulising Crohn's disease.A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.The occurrence and prevention of foodborne disease in vulnerable people.Immune Alterations in Patients with Anti-Interferon-γ AutoantibodiesEpstein-barr virus reactivation after infliximab in rheumatoid arthritis: a case report.TNFalpha blockade in human diseases: an overview of efficacy and safety.Legionella pneumophila serotype 1 pneumonia in patient receiving adalimumabOverlapping presentation of fungal tubulointerstitial nephritis in an immunosuppressed pediatric patientDo RANKL inhibitors (denosumab) affect inflammation and immunity?A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009.Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.Diagnosis and management of infectious complications of childhood rheumatic diseases.Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy.The emerging problem of biological treatment in migrant and travelling populations: it is time to extend guidelines for the screening of infectious diseases.Cytomegalovirus, inflammatory bowel disease, and anti-TNFα.Endophthalmitis associated with Purpureocillium lilacinum during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy.Comparison of the risk of infections in different anti-TNF agents: a meta-analysis.Pulmonary actinomycosis complicating infliximab therapy for Crohn disease.Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?Biological therapy of psoriasis.[Legionella pneumonia after infliximab in a patient with rheumatoid arthritis].Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.A life-threatening abscess in a patient treated with a tumour necrosis factor-alpha antagonist: a case report.Parapharyngeal abscess in a patient receiving etanercept.Staphylococcus aureus thymic abscesses associated with anti-tumour necrosis factor therapy.Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans.Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases.[A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy].Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist.Case of Legionella pneumophila pneumonia (legionellosis) developed in a psoriatic arthritis patient receiving adalimumab.Diagnosis and Treatment of Non-European Fungal Infections
P2860
Q24675642-D886DFAA-F448-401C-A39E-7B807E8AE6BAQ28475948-0ED152B5-170D-46A4-BB17-8ECD83787809Q29302324-DDA71925-7600-416A-815A-996A7A461B73Q30479123-47FB548F-ACC8-47F0-A10B-1045EB1A7240Q30590322-24EF19D8-215F-444E-84A7-FFCFB8F51874Q33157116-78935DC2-E88E-412E-A2B0-1BFB3134CC67Q33875118-0B51094B-AC21-4078-92CE-C9AE1F674439Q34525280-65772AB3-9D1C-4232-AA9F-63EC6FEF023CQ35152199-EE026B61-C5AB-4A8B-B1A3-203433B3F5D3Q35173590-D5F3BF45-167A-4227-9903-3499F251030BQ35884214-B20BCA24-5CC1-4BBC-9E6D-426E5599E858Q35912103-00E36D36-8A7E-4419-855B-16DEA04D12BBQ36536861-7DCE9D65-C2DD-4BB9-B87B-AA14529CBB8CQ36574293-35F0F670-3DFD-49AD-B06D-89C3355A9EF6Q37229955-BA590AA5-8EB8-4A6D-BFFC-D504542021C3Q37767159-17AF59D7-0AED-4180-81BA-BC620C22881EQ37814549-25161E9F-33F5-4DE0-86AD-FC0A894F4766Q37869451-388AC236-6B9F-43E5-A6E0-B57671F805CBQ38069890-1D3DB821-598C-493A-A468-B1DB659E3644Q38084889-C2D19594-BE7F-4272-B984-7173AE94ACFDQ38108468-939DE24A-A6A9-4FC3-9263-70456178B619Q38171157-951E7EC9-CCF4-4882-9F52-C3E650D539CFQ39022584-92827713-5052-414B-9E36-199615864552Q40242971-2DD17E3B-738E-44B0-8BB6-320D7A4EEA5BQ40345791-EE0C3092-2BA7-4F2B-ADAA-BA6FEF3109B3Q40400866-B2660E70-B786-4E55-A130-B5A79D7D9197Q40672157-5833035D-242B-4FD0-9B58-F97BF4465504Q41145989-9AB539D2-68F9-44AF-BF38-0414990B4EAFQ41518551-B26DF515-DA80-493A-99A6-F628E77D9234Q41819384-03AD3607-B39B-4D00-8214-29B474BEB2ACQ43282843-891D8BFB-A3E9-411D-867B-A776DE8C078FQ43445519-000F684B-06D3-4E7A-9BAF-36194FF903E8Q44647125-2103485A-0773-42F0-BA80-FD2D98DB2272Q44910278-539D3094-CC90-45EC-B803-D41413F8552DQ45095583-B78730BB-22A0-42AA-AB3F-AC279E7067C5Q46986955-E16735CE-59A5-479B-8CDF-4C1EFEA350F3Q50073115-E180840A-CBDD-493A-B873-5373E6F4FCDDQ54291465-42AF5943-0D06-4EA9-8860-2C4B6E570849Q58827586-269CC463-BA0B-45DB-A71F-BD434640AD28
P2860
Infections associated with tumor necrosis factor-alpha antagonists.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Infections associated with tumor necrosis factor-alpha antagonists.
@ast
Infections associated with tumor necrosis factor-alpha antagonists.
@en
type
label
Infections associated with tumor necrosis factor-alpha antagonists.
@ast
Infections associated with tumor necrosis factor-alpha antagonists.
@en
prefLabel
Infections associated with tumor necrosis factor-alpha antagonists.
@ast
Infections associated with tumor necrosis factor-alpha antagonists.
@en
P2093
P1433
P1476
Infections associated with tumor necrosis factor-alpha antagonists.
@en
P2093
Edith R Lederman
Mark R Wallace
Nancy F Crum
P304
P356
10.1097/01.MD.0000180044.19285.9A
P407
P577
2005-09-01T00:00:00Z